RxDoctor Payments DataLook up a doctor →

Brandy Hood, MD

Urology · Nashville, TNNPI 1639515786

Payments from drug & device makers

$72,682in general payments, 2019–2025

Across 346 payments — averaging $210.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$63K
  • Axonics, Inc.$3K
  • Boston Scientific$990
  • Astellas Pharma US Inc$961
  • Coloplast$905
  • Myovant Sciences Inc.$404
  • plus $3K from 38 others

What the payments were for

  • Travel & lodging$2,41024%
  • Food & beverage$7,27073%
  • Education$2543%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$72,682 in reported general payments places this provider in the 85th percentile of 276 urology providers in Tennessee.

See all urology providers in Tennessee

Medicare billing

Part B allowed, 2024
$186,469
Medicare patients
502
Services billed
8,420

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron192$118,525
GemtesaVibegron177$104,563
Methenamine Hippurate306$16,564
Estradiol131$9,651
PremarinEstrogens, Conjugated19$8,395
Trospium Chloride ErTrospium Chloride40$6,551
Trimethoprim107$4,863
Solifenacin Succinate111$3,309
Potassium Citrate ErPotassium Citrate27$2,436
Oxybutynin Chloride ErOxybutynin Chloride96$2,399
NitrofurantoinNitrofurantoin Macrocrystal89$2,200
Tamsulosin Hcl166$1,925
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst74$1,162
Ciprofloxacin Hcl170$811
Cephalexin205$680

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$961$118,525192 claims
Sumitomo Pharma America, Inc.Gemtesa$397$104,563177 claims
PfizerPremarin$92$8,39519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 276 urology providers in Tennessee.

Other urology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →